Last 28 quarters of trend data · Healthcare · Medical - Healthcare Information Services
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 38.45 | 36.00 | 144.12 | 42.61 | 330.47 | 34.58 | 36.75 | 58.13 | 54.91 | 97.50 | — | — | — | 9.86 | — | — | — | — | 161.08 | — | — |
| — | +4.1% | +292.2% | -26.7% | +501.9% | -64.5% | — | — | — | +889.1% | — | — | — | — | — | — | — | — | -93.6% | — | — | |
| P/S Ratio | 1.43 | 1.25 | 0.86 | 1.19 | 1.88 | 2.19 | 2.06 | 2.25 | 3.45 | 3.74 | 3.50 | 3.41 | 3.23 | 3.01 | 3.50 | 2.61 | 2.57 | 3.18 | 10.16 | 15.73 | 21.61 |
| — | -42.9% | -58.2% | -47.2% | -45.6% | -41.4% | -41.1% | -34.1% | +6.8% | +24.1% | -0.1% | +30.9% | +25.6% | -5.2% | -65.5% | -83.4% | -88.1% | -85.5% | -61.1% | -40.3% | -44.4% | |
| P/B Ratio | 1.90 | 1.55 | 1.08 | 1.50 | 2.45 | 2.77 | 2.56 | 2.46 | 3.87 | 4.48 | 4.39 | 3.52 | 2.64 | 2.55 | 3.12 | 2.35 | 2.45 | 2.98 | 10.50 | 16.13 | 19.93 |
| — | -44.0% | -58.0% | -39.1% | -36.7% | -38.3% | -41.7% | -30.1% | +46.6% | +75.5% | +40.9% | +49.5% | +8.0% | -14.4% | -70.3% | -85.4% | -87.7% | -84.1% | -53.1% | -29.1% | -31.0% | |
| P/FCF | 6.92 | 3.11 | — | 13.53 | 6.34 | 14.22 | — | 15.87 | 7.80 | — | 31.51 | 223.73 | 12.48 | 38.36 | 35.80 | 28.91 | 24.16 | 16.34 | 116.67 | 82.73 | 105.30 |
| — | -78.1% | — | -14.7% | -18.7% | — | — | -92.9% | -37.5% | — | -12.0% | +673.9% | -48.3% | +134.7% | -69.3% | -65.1% | -77.1% | -88.2% | -0.4% | -89.7% | -71.1% | |
| EV / EBITDA | 8.21 | 12.32 | 5.90 | 6.57 | 12.09 | 10.78 | 10.81 | 12.60 | 18.56 | 21.60 | 31.58 | 26.86 | — | 15.81 | 24.13 | 27.19 | — | 64.97 | 65.17 | 147.07 | 242.69 |
| — | +14.3% | -45.4% | -47.9% | -34.9% | -50.1% | -65.8% | -53.1% | — | +36.6% | +30.9% | -1.2% | — | -75.7% | -63.0% | -81.5% | — | -86.3% | -99.4% | — | — | |
| EV / EBIT | 16.21 | 12.32 | 15.82 | 12.24 | 25.74 | 16.87 | 17.52 | 20.63 | 34.41 | 30.36 | 49.31 | — | — | 21.43 | 37.85 | 65.38 | — | — | 102.41 | 279.87 | 593.92 |
| — | -27.0% | -9.7% | -40.7% | -25.2% | -44.4% | -64.5% | — | — | +41.7% | +30.3% | — | — | — | -63.0% | -76.6% | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 92.8% | 89.5% | 78.4% | 91.0% | 93.2% | 83.7% | 93.4% | 93.9% | 94.0% | 94.1% | 93.7% | 92.3% | 89.6% | 91.4% | 90.9% | 90.6% | 90.7% | 90.6% | 94.0% | 93.5% | 94.2% |
| — | +6.9% | -16.1% | -3.0% | -0.9% | -11.0% | -0.3% | +1.7% | +4.9% | +3.0% | +3.1% | +1.9% | -1.2% | +0.9% | -3.2% | -3.1% | -3.7% | -3.3% | +0.5% | -0.6% | -0.4% | |
| Operating Margin | 11.0% | 11.8% | 10.1% | 11.6% | 7.5% | 13.6% | 11.5% | 9.2% | 10.5% | 9.9% | 3.7% | -9.3% | -21.3% | 9.7% | 6.1% | 0.9% | -8.4% | -2.1% | 9.7% | 5.5% | 3.6% |
| — | -13.6% | -12.5% | +27.2% | -28.6% | +37.7% | +208.8% | +198.4% | +149.1% | +2.7% | -39.3% | -1085.7% | -153.9% | +557.5% | -36.8% | -82.9% | -333.8% | -961.9% | +412.0% | +102.8% | +108.2% | |
| Net Margin | 3.8% | 4.3% | 0.6% | 2.8% | 0.6% | 6.3% | 5.4% | 3.4% | 6.3% | 3.3% | -0.5% | -13.2% | -21.4% | 31.0% | -1.8% | -1.1% | -22.3% | -0.7% | 6.0% | -18.7% | -9.3% |
| — | -32.7% | -88.9% | -17.9% | -90.9% | +89.5% | +1167.9% | +125.8% | +129.4% | -89.2% | +71.5% | -1128.2% | +4.0% | +4300.7% | -129.6% | +94.3% | -140.6% | -104.2% | +481.5% | +90.4% | +74.0% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 4.5% | 1.3% | 0.2% | 0.9% | 0.2% | 2.0% | 1.6% | 0.9% | 1.8% | 1.0% | -0.1% | -3.1% | -4.3% | 6.8% | -0.4% | -0.2% | -5.2% | -0.2% | 1.5% | -4.8% | -2.2% |
| — | -32.1% | -88.2% | -6.0% | -90.0% | +92.3% | +1206.2% | +130.1% | +141.4% | -84.9% | +63.8% | -1179.9% | +16.6% | +3968.7% | -126.4% | +94.8% | -140.2% | -104.5% | +565.2% | +88.3% | +89.9% | |
| ROA | 2.2% | 0.4% | 0.1% | 0.4% | 0.1% | 1.0% | 0.8% | 0.5% | 0.9% | 0.5% | -0.1% | -1.6% | -2.3% | 3.6% | -0.2% | -0.1% | -2.6% | -0.1% | 0.8% | -2.5% | -1.1% |
| — | -60.2% | -91.7% | -19.1% | -90.2% | +115.0% | +1342.5% | +131.3% | +138.3% | -87.2% | +67.4% | -1171.8% | +14.3% | +4036.8% | -126.0% | +95.0% | -134.1% | -104.5% | +604.1% | +87.4% | +76.9% | |
| ROIC | 7.6% | 1.9% | 1.6% | 1.9% | 1.2% | 2.3% | 2.0% | 1.7% | 1.8% | 1.8% | 0.7% | -1.7% | -3.5% | 1.7% | 1.1% | 0.2% | -1.5% | -0.4% | 2.4% | 1.4% | 0.8% |
| — | -15.4% | -21.5% | +15.4% | -32.9% | +28.3% | +197.3% | +197.1% | +152.5% | +6.6% | -36.8% | -1109.4% | -129.2% | +496.6% | -54.7% | -88.2% | -284.4% | -785.0% | +391.2% | +102.7% | +106.5% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.88 | 0.83 | 0.87 | 0.88 | 0.91 | 0.85 | 0.83 | 0.75 | 0.78 | 1.06 | 1.13 | 0.93 | 0.81 | 0.80 | 0.87 | 0.88 | 0.89 | 0.86 | 0.89 | 0.84 | 0.83 |
| — | -2.3% | +5.2% | +17.5% | +16.1% | -19.4% | -26.5% | -19.6% | -3.1% | +32.4% | +30.1% | +6.1% | -8.9% | -6.8% | -2.8% | +4.2% | +6.8% | +0.3% | -5.5% | -14.8% | -14.5% | |
| Debt / EBITDA | 3.14 | 21.32 | 13.10 | 11.84 | 15.12 | 11.54 | 12.22 | 14.58 | 14.35 | 19.20 | 30.45 | 28.08 | — | 20.17 | 27.28 | 41.52 | — | 75.55 | 22.49 | 31.35 | 40.90 |
| — | +84.7% | +7.2% | -18.7% | +5.4% | -39.9% | -59.9% | -48.1% | — | -4.8% | +11.6% | -32.4% | — | -73.3% | +21.3% | +32.4% | — | -14.0% | -98.8% | — | — | |
| Current Ratio | 2.61 | 1.38 | 1.47 | 2.61 | 3.11 | 4.21 | 5.23 | 5.32 | 5.48 | 7.32 | 6.29 | 7.12 | 8.23 | 11.14 | 13.15 | 12.05 | 10.34 | 11.23 | 16.76 | 13.42 | 14.47 |
| — | -67.2% | -71.8% | -50.9% | -43.3% | -42.6% | -16.9% | -25.3% | -33.4% | -34.2% | -52.2% | -40.9% | -20.4% | -0.8% | -21.5% | -10.2% | -28.5% | -31.6% | -6.0% | -26.4% | -26.3% | |
| Quick Ratio | 2.61 | 1.38 | 1.47 | 2.61 | 3.11 | 4.21 | 5.23 | 5.32 | 5.48 | 7.32 | 6.29 | 7.12 | 8.23 | 11.14 | 13.15 | 12.05 | 10.34 | 11.23 | 16.76 | 13.42 | 14.47 |
| — | -67.2% | -71.8% | -50.9% | -43.3% | -42.6% | -16.9% | -25.3% | -33.4% | -34.2% | -52.2% | -40.9% | -20.4% | -0.8% | -21.5% | -10.2% | -28.5% | -31.6% | -6.0% | -26.4% | -26.3% | |
| Interest Coverage | 2.33 | 2.58 | 1.58 | 2.36 | 1.56 | 2.82 | 2.57 | 2.00 | 1.66 | 1.80 | 1.02 | -0.66 | -2.17 | 1.86 | 1.27 | 0.60 | -1.35 | -0.46 | 3.38 | 1.99 | 1.18 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 28 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying GDRX stock.
GoodRx Holdings, Inc.'s current P/E is 38.5x. The average P/E over the last 4 quarters is 138.3x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
GoodRx Holdings, Inc.'s current operating margin is 11.0%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking GoodRx Holdings, Inc.'s business trajectory between earnings reports.